期刊文献+

吡柔比星联合苏拉明对人膀胱癌裸鼠移植瘤的实验研究 被引量:1

Inhibitory Effects of Pirarubicine Combined with Suramin on T24 Bladder Carcinoma in Nude Mice
原文传递
导出
摘要 目的:研究吡柔比星联合苏拉明对人膀胱癌裸鼠移植瘤的影响。方法:将24只BALB/c裸鼠T24人膀胱癌细胞接种后随机分为对照组、吡柔比星组、苏拉明组、吡柔比星和苏拉联合用药组(联合治疗组)(每组n=6)给予不同处理,观察各组裸鼠移植瘤用药后的生长曲线变化。4周后处死取出肿瘤组织:测量肿瘤大小、重量并计算抑瘤率;采用免疫组化检测肿瘤组织微血管密度(Microvessel density,MVD)、流式细胞分析仪细胞凋亡、反转录酶-聚合酶链锁反应(Reverse transcription-polymerase chain reaction,RT-PCR)检测各组肿瘤组织中成纤维细胞生长因子(Basic fibroblast growth factor,b FGF)和血管内皮生长因子(Vascular endothelial growth factor,VEGF)m RNA的表达。结果:联合治疗组肿瘤生长曲线明显慢于其它各组;联合治疗组抑瘤率(56.03%)明显高于吡柔比星组(30.12%)、苏拉明组(35.32%)抑瘤率(P<0.05);吡柔比星组、苏拉明组及联合治疗组MVD值分别为13.01±2.98、11.32±2.11、8.82±0.77,与对照组MVD(19.88±2.62)相比明显下降(P<0.05);流式细胞仪检测凋亡显示联合治疗组细胞凋亡率(38.57±3.98)明显高于吡柔比星组(14.78±2.95)、苏拉明组(20.92±3.67)及对照组(10.03±1.34)(P<0.05);RT-PCR结果显示,联合治疗组b FGF和VEGF表达量明显降低。结论:吡柔比星和苏拉明联合应用在体内能抑制膀胱癌裸鼠移植瘤的生长、诱导肿瘤细胞的凋亡和抑制肿瘤血管生成。 Objective: To evaluate the inhibitory effect of pirarubicine(THP) combined with suramin on T24 bladder carcinoma in nude mices. Methods: 24 BALB/c nude mice with T24 tumor cells inoculation were randomly divided into control group, THP group,suramin group, THP and suramin group(combined treatment group)(all n=6). The changes of growth curve were measured. After four weeks, observation, the mice were sacrificed and the tumors were dissected to measure size, weight and tumor inhibition rate. The microvessel density(MVD) were analysed by using CD34 immunohistochemistry and cell apoptosis were detected by using flow cytometry. Finally, the expression of basic fibroblast growth factor(b FGF) and vascular endothelial growth factor(VEGF) were measured by reverse transcription-polymerase chain reaction(RT-PCR). Results: Tumor growth curve of combined treatment group was obviously slower than that of the other groups. The tumor inhibition rate of combined treatment group was 56.03%, which was significant significance than that in THP group(30.12%) and suramin group(35.32%)(P〈0.05). The MVD in THP, suramin and combination groups were 13.01 ±2.98, 11.32 ±2.11, and 8.82 ±0.77, respectively, which was decreased compared to that in the control group(19.88 ±2.62)(P〈0.05). The apoptosis rate in combination group(38.57 ±3.98) was significantly higher than that in THP group(14.78 ±2.95), suramin group(20.92 ±3.67), and control group(10.03 ±1.34)(P〈0.05). The expression of b FGF and VEGF in combined treatment group was decreased than in other groups. Conclusions: THP combined with suramin could inhibit the tumor growth,induce tumor cell apoptosis and suppress angiogenesis in nude mice.
出处 《现代生物医学进展》 CAS 2015年第16期3049-3052,3068,共5页 Progress in Modern Biomedicine
基金 广东省科技计划项目(2011B031800309)
关键词 膀胱癌 裸鼠 吡柔比星 苏拉明 移植瘤 Bladder Carcinoma Nude mice Pirarubicine Suramin Xenograft tumor
  • 相关文献

参考文献23

  • 1Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002 [J]. CA Cancer J Clin, 2005, 55(2): 74-108.
  • 2Heney NM. Natural history of superficial bladder cancer: Prognostic features and long-term disease course [J]. Urot Clin North am, 1992, 19(3): 429-433.
  • 3Masson-Lecomte A, Rava M, Real FX, et al. Inflammatory Biomarkers and Bladder Cancer Prognosis: A Systematic Review [J]. Eur Urol, 2014[Epub ahead of print].
  • 4DeSouza K, Chowdhury S, Hughes S. Prompt diagnosis key in bladder cancer[J]. Practitioner, 2014, 258(1767): 23-27.
  • 5郭正辉,梅骅,黄健,李泗耀.VEGF和bFGF在浅表膀胱移行细胞癌中的表达及意义[J].癌症,2003,22(3):307-309. 被引量:8
  • 6Martin LK, Bekaii-Saab T, Sema D, et al. A phase i dose escalation and pharmacodynamic study of su5416 (semaxanib) combined with weekly cisplatin and irinotecan in patients with advanced solid tumors [J]. Onkologie, 2013, 36(11): 657-660.
  • 7Piirsoo A, Kasak L, Kauts ML, et al. Protein kinase inhibitor su6668 attenuates positive regulation ofgli proteins in cancer and multipotent progenitor cells[J]. Biochim Biophys Acta, 2014, 1843(4): 703-714.
  • 8Tomaszewski JJ, Smaldone MC. Emerging intravesical therapies for management of nonmuscle invasive bladder cancer[J]. Open Access J Urol, 2010, 19(2): 67-84.
  • 9Xin Y, Lyncss G, Chcn D, et al. Low dose suramin as a chcmoscnsitizer of bladder cancer to mitomycin C [J]. J Urol, 2005, 174(1): 322-327.
  • 10张平,贺兼斌,欧立文,王小华.苏拉明联合顺铂对肺腺癌小鼠移植瘤生长和转移的影响[J].癌症,2006,25(4):409-413. 被引量:10

二级参考文献26

  • 1张广健,吴长利,韩瑞发,赵玉干,马腾骧,王广有,王凡.膀胱肿瘤抗药机制的实验研究[J].中华泌尿外科杂志,1996,17(4):203-206. 被引量:26
  • 2贺兼斌,张平,王小华,欧立文,龙治峰.槲皮素联合苏拉明对肺腺癌小鼠移植瘤生长的抑制作用[J].肿瘤,2006,26(4):322-326. 被引量:8
  • 3卫旭东,周梁,程磊,田洁.CD133作为喉癌肿瘤起始细胞标志的实验研究[J].中华耳鼻咽喉头颈外科杂志,2006,41(12):940-944. 被引量:17
  • 4张兆伟 张金芝 等.小鼠肺腺癌(LA-795)细胞株的建立及一些生物学特性的研究[J].中华肿瘤杂志,1985,7(2):83-83.
  • 5顾方六.膀胱肿瘤[A].见:吴在德主编.外科学 :第 5版[C].北京:人民卫生出版社,2000.766- 769.
  • 6[1]Carmeliet P, Collen D. Molecular analysis of blood vessel formation and disease. Am J Physiol, 1997,273:2091-2104.
  • 7[2]Dvorak H, Brown L, Detmar M, et al. Vascular permeability factor/ Vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol,1995,146:1029-1039.
  • 8Konno H.Antitumor effect of the angiogenesis inhibitor TNP-470 on human digestive organ malignancy[J].Cancer Chemother Pharmacol,1999,43 (suppl):S85-89.
  • 9Weidner N.Tumor angiogenesis:review of current application in tumor prognosis[J] Semin Diagn Pathol,1993,10(4):302-313.
  • 10Kwak B K,Shim H J,Park E S,et al.Hepatocellular carcinoma:correlation between vascular endothelial growth factor level and degree of enhancement by multiphase contrastenhanced computed tomography[J].Invest Radiol,2001,36(8):487-492.

共引文献30

同被引文献6

引证文献1

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部